{"id":"NCT00712985","sponsor":"Milton S. Hershey Medical Center","briefTitle":"Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)","officialTitle":"Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2008-07-11","resultsPosted":"2014-04-24","lastUpdate":"2014-04-24"},"enrollment":18,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Zometa","otherNames":["Zoledronic Acid"]}],"arms":[{"label":"Zometa (Zoledronic Acid) X 1 dose","type":"EXPERIMENTAL"}],"summary":"The purpose of this research is to establish if a once a year dose of Zoledronic Acid is sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx within normal range at 12 months post-dosing in postmenopausal early breast cancer patients receiving additional treatment with non-steroidal aromatase inhibitors.","primaryOutcome":{"measure":"Number of Participants With Urine and Serum NTx and Serum CTx Within Normal Range at 12 Months","timeFrame":"One year","effectByArm":[{"arm":"Zoledronic Acid 5 mg IV","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":8,"exclusionCount":23},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["12090977","14551341","15014181","12356057","12771706"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":17},"commonTop":[]}}